Vikram Sharma, MD
Interventional Cardiology · Iowa City, IANPI 1104232412
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.9%), grants and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 63.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $2,069 and has fallen 93.4% since, to $137 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.
Across 48 payments — averaging $70.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abbott$588
- Abiomed$293
- Acist Medical Systems, Inc.$122
- Penumbra, Inc.$63
- Getinge USA Sales, LLC$51
- plus $131 from 4 others
What the payments were for
- Grants$1,12633%
- Travel & lodging$48014%
- Food & beverage$1,35140%
- Education$43013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $2,140 |
| Abbott | 6 | $588 |
| Abiomed | 9 | $293 |
| Acist Medical Systems, Inc. | 1 | $122 |
| Penumbra, Inc. | 1 | $63 |
| Getinge USA Sales, LLC | 3 | $51 |
| Edwards Lifesciences | 1 | $45 |
| Medtronic | 2 | $33 |
| Biotronik Inc. | 2 | $28 |
| Shockwave Medical, Inc | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,388 in reported general payments places this provider in the 45th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 65 | $596 |
| Metoprolol Succinate | 11 | $195 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 23 | $111 |
| Furosemide | 26 | $86 |
| Spironolactone | 18 | $59 |
| Atorvastatin Calcium | 20 | $49 |
| Amlodipine Besylate | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Iowa City
- Jason AllenIowa City$30K
- Hossein OuranosIowa City$28K
- Spas KotevIowa City$12K
- Waqas SiddiquiIowa City$10K
- Hisham IbrahimIowa City$8K
- Yehia SalehIowa City$6K
- James RossenIowa City$5K
- Connor YoungIowa City$4K
- Phillip HorwitzIowa City$3K
- Ahmad ArhamIowa City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.